• linkedin
  • Increase Font
  • Sharebar

    Does dexamethasone implant add benefit in ranibizumab patients?


    Published findings

    The DCRC Network investigators reported their findings in JAMA Ophthalmol (2018; 136: 29-38).

    At 6 months, the mean improvement in visual acuity was 2.7 letters in the combination group and 3 letters in the ranibizumab-only cohort. Baseline visual acuity was similar at 66 letters in both groups.

    There was also no difference found when controlling for confounding factors, such as lens status. The patients in the combination group had a greater chance of improving >15 letters (P = 0.03), but they also had an increased chance of losing 10 or more letters. At 24 weeks, the patients in the combination cohort had a greater decrease in CST (110 µm versus 62 µm).

    In the dexamethasone group, 29% of patients experienced an increase in IOP, defined as any visit with an IOP > 30 mm Hg, a >10 mm Hg increase from baseline, or if the patient was initiated on an IOP-lowering agent (P <0.001).


    Lynda Charters
    Lynda Charters is a freelance medical writer.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';